• detect early signs of developing cancer • help monitoring existing cancers • produce an individual profile of chemopherapeutic drugs and natural substances that can be used to achieve the best treatment outcomes.
Circulating Tumor Cells (CTCs) are cells that have detached from the primary tumor and flow into the blood or lymphatic circulation creating a secondary tumor. Despite their rare population, these cells exhibit metastatic attributes and are related to cancer progression. Detecting and isolating them is the priority of many research projects and although there has been great progress made in this area there are many drawbacks associated with sensitivity and specificity of different methodologies. R.G.C.C. Group has established a new alternative fluidic-based method with 86.6% sensitivity and 83.3% specificity among different types of cancer.R.G.C.C. Groups’s platform, lacking enrichment steps has the ability to offer a precise and accurate detection and isolation of CTCs in blood.
There is a growing interest in personalized cancer treatments and the identification of suitable treatments that may work for each cancer patient. Chemosensitivity testing is one method of doing this. Oncologists primarily rely on the statistical analysis of large treatment trials to decide which drugs to use for specific cancers. Chemosensitivity testing involves testing an individual’s cancer cells in the laboratory to identify which drugs and natural substances demonstrate the best response. The R.G.C.C Group test is a blood test (or in some cases tissue tests). Tumor cells are identified and isolated from the sample for the following analysis: • Viability testing of chemotherapy drugs • Genetic profiling for guidance about targeted therapies e.g. monoclonal antibodies • Viability testing (and identification of mechanisms of action), of natural substances which may be used as part of a complementary treatment strategy. The results are presented in a written report which the doctor can use to help guide treatment options and choices. In addition, R.G.C.C. Group can provide information about how an individual will ‘handle’ specific chemotherapy agents. Our genetic make-up determines whether we are ‘accumulators’ or ‘rapid metabolizers’ of certain drugs. This can play a critical role in determining how effective a specific treatment is likely to be for us, and how significant the side effects will be.
It is well established by literature and validation that the overall response rate from empirical chemotherapy varies from 5 to 7.5% (Royal North Shore Hospital ClinOncol (R Coll Radiol) 2005 Jun;17(4):294). Pharmaceutical industry assesses and validates candidate drugs by utilizing extensive chemosensitivity assays under the term of High Throughput Screening (HTS). Cancer is caused by severe damaged genetic material which leads to random genetic instability. So, each malignancy behaves differently to each individual. Each person has different genetic fingerprinting from others.
The tumor is consisted of several subgroups of cells (subpopulations) with different features. One of the subset actually drives the progress of the disease, the resistance to therapy and the relapse. This subset is called cancer stem cell like cells ortumor initiating cells. When a patient is treated and the cancer cells may be destroyed, then when the compatible diagnostic does not discover any signal, the cancer cells may consist a population of 10^9 to 10^12 cells. This limit defines the remission stage of a patient. At that stage only the cancer stem cells may survive and colonize into distant organs and generate metastases in time. Hence the usage of our test is to detect in which therapeutic approach the cancer cell may respond and also during remission, it is essential to detect, discover and explore the features of the disseminated cancer stem cell like, in order to delay further the risk of relapse and also to generate options to treat even these kinds of cells. The main goal is to discover, analyze and screen the cancer cells in every step of the disease.
• Onconomics or • Onconomics Plus
• Oncocount R.G.C.C. or• Oncotrace R.G.C.C. or• Oncotrail R.G.C.C. only for known and specific types of malignancies
For the first year every trimester and then every half year.
For a period of three years a Meta analysis has been conducted comparing CTCs profile and metastases profile in order to detect potent markers that are relevant with the site of relapse. Metastat tests provides this information.